

2023 Questionnaire

for the April 2023 Insurance Capital Standard (ICS) Data Collection Exercise of the Monitoring Period Project

("the ICS Questionnaire")

The ICS Questionnaire has been developed as a supporting document for groups participating in the 2023 ICS Data Collection Exercise and must be read in conjunction with the associated ICS Technical Specifications Part 1 and Part 2, ICS data collection Template and Yield Curve documentation. All documents are provided for information only.

These documents do not replace or supersede the ICS Level 1 and Level 2 documents, which have been agreed and published by the IAIS.



Contents

| 1 | Introduction | | | | |
|----|------------------|---|----|--|--|
| 2 | 2 Identification | | | | |
| 3 | Ge | eneral Questions | 5 | | |
| 4 | Pe | erimeter of the ICS Calculation | 9 | | |
| 5 | Ma | arket-Adjusted Valuation | 11 | | |
| 6 | Ca | apital Requirement | 12 | | |
| | 6.1 | Equity risk charge | 12 | | |
| | 6.2 | Self-assessment template for natural catastrophe models | 13 | | |
| | 6.3 | Non-insurance risk charges | 17 | | |
| 7 | Ad | dditional Reporting | 19 | | |
| | 7.1 | GAAP Plus | 19 | | |
| | 7.1 | 1.1 Reconcilations | 29 | | |
| 8 | Int | ternal Models | 34 | | |
| 9 | Se | elf-assessment Template for Internal Models | 38 | | |
| 10 |) | Economic impact assessment | 45 | | |
| | Impa | act on product availability | 45 | | |
| | Impa | act on insurers' business models | 49 | | |
| | Impa | act on financial markets | 54 | | |
| | Imple | ementing the ICS | 57 | | |



1 Introduction

This Questionnaire focuses on supplementary information in relation to data provided in the Template for the April 2023 ICS Data Collection Exercise of the Monitoring Period Project, and is due **31 August 2023**.



2 Identification

| 1 | Please provide the name of your IAIG | | | Volunteer Group below: |
|---|--|---------------------|-------------|---|
| | IAIG / Volunteer Group name | | oup name | |
| | | Insert text | | |
| 2 | | | | n of this questionnaire (dd/mm/yyyy). If an earlier been updated please indicate a new date here: |
| | | Date of this submis | ssion | |
| | | Insert text | | |
| 3 | Please indicate the name of the conta Questionnaire, including email addres | | | ct persons for queries about the responses to this and telephone number. |
| | | Primary Contact | Information | |
| | | Name: | Insert text | |
| | | Email: | Insert text | |
| | | Phone: | Insert text | |
| | | | | |
| | Backup ContactInformationName:Insert text | | | |
| | | | | |
| | | Email: | Insert text | |
| | | Phone: | Insert text | |



3 General Questions

| Template sheet(s) referred to in this section: | Various |
|---|---------|
| Key Technical Specification section(s) relevant to this section | Various |

| 4 | Were any material assumptions or simplifications used when providing data on the reference ICS (Technical Specifications – Part 1)? Examples of assumptions or simplifications follow the questions. | | | | | |
|--|---|-------------------|--|--|--|--|
| | Provide your re | sponse by placin | g an 'x' in the relevant cell: | | | |
| | YES NO Not Applicable | | | | | |
| | If YES, complete | the following que | estion for each material assumption or simplification used. | | | |
| Please specify the item or issue, including a reference to the Technical Specifications and provide a description with sufficient detail to allow an assessment of materiality an impact. In the description, also indicate whether you anticipate future reliance on the a simplification or was it due to circumstances such as a resource constraint. | | | | | | |
| | Item name | Reference | Description | | | |
| | Insert text | Insert text | Insert text | | | |
| | (Add additional r | rows as necessal | y) | | | |
| | Examples where | assumptions or | simplifications may have been used: | | | |
| | ICS Adjustments – Was difficulty encountered being able to offset in the ICS Adjustment where an assumption or simplification was | | | | | |
| 5 | Were any material assumptions or simplifications used when providing data on the candidate ICS as a PCR (Technical Specifications – Part 2)? Examples of assumptions or simplifications follow the questions. | | | | | |
| | Provide your re | sponse by placin | g an 'x' in the relevant cell: | | | |
| | YES | NO | Not Applicable | | | |
| | If YES, complete | the following que | estion for each material assumption or simplification used. | | | |
| | • • | | ncluding a reference to the Technical Specifications or Template, ficient detail to allow an assessment of materiality and potential | | | |



| | impact. In the description, also indicate whether you anticipate future reliance on the assumption or simplification or was it due to circumstances such as a resource constraint. | | | | | |
|---|---|----------------------|---|---|--|--|
| | Item name | Reference | Description | | | |
| | Insert text | Insert text | Insert text | | | |
| | (Add additional re | ows as necessar | <i>y)</i> | | | |
| | Examples where | assumptions or s | simplifications | may have been used: | | |
| | | | om the ICS Adjustments – Was difficulty encountered being able to offset sing from the ICS Adjustment where an assumption or simplification was | | | |
| 6 | - | data between Y | ears 3 and 4 | cifications – Part 1), were any material changes of the Monitoring Period (eg simplifications that were | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please specify the item or issue, including a reference to the Technical Specifications of Template, and provide a description as well as rationale for its relevance to analysis. Please describe in summary, but with sufficient detail to allow an assessment of materiality an potential impact. | | | | | |
| | Item name | Referen | ce | Description and rationale | | |
| | Insert text | Insert te | ext | Insert text | | |
| | (Add additional rows as necessary) | | | | | |
| 7 | Did you have any difficulties interpreting and/or applying the main changes between ICS Version 2.0 and the candidate ICS as a PCR (which appear in tracked changes in the Technical Specifications – Part 2)? | | | | | |
| | Provide your response by placing an 'x' in the relevant cell: | | | | | |
| | YES NO Not Applicable | | | | | |
| | If YES, please sp | ecify the difficulti | es encountere | ed for each of the items listed in the table below. | | |
| | Item name | Referen | се | Description | | |



| MAV – Middle bucket criteria | §§120-121 | |
|--|-------------------------------|--|
| If relevant, please provide the type of product, the difficulties and whether these difficulties blocked these products from entering the Middle Bucket. | | |
| MAV – Middle Bucket spread adjustment | Section 5.2.5.3.2.3 | |
| MAV – General Bucket spread adjustment | Section 5.2.5.3.2.4 | |
| MAV – Modulation factor | Section 5.2.5.3.2.5 | |
| Capital resources – Tier 1 limited criteria | §§193-194 | |
| Capital resources – Tier 2 Paid-up criteria | §§195-197 | |
| Capital resources – Limit on non- controlling interests | Section 6.4.4 | |
| Non Default Spread Risk | Section 7.3.3 | |
| Equity risk – differentiated treatment for infrastructure equity | Section 7.3.4 and Annex 3 | |
| Equity risk – Neutral Adjusted Dampener | Section 7.3.4 | |
| Credit risk – differentiated | §491, Table 26 and Annex 3 | |



| | treatment for infrastructure debt | | | | | |
|---|---|----------------------------|---------------------------|--|--|--|
| | Non-insurance risk charge – treatment of non-insurance non-banks | §§599 and 601 | | | | |
| | Tax effect on the ICS Capital requirement | §§636 and 637 | | | | |
| | Other methods – Use of Supervisor-Owned and Controlled Credit Assessments | | | | | |
| | Other methods – Use of internal models | Section 9.2 and Annex 4 | | | | |
| 8 | Do you have further comments regarding the candidate ICS as a PCR not specifically addressed elsewhere in the Questionnaire? Where appropriate, this includes comments on data, additional relevant data, and/or calculations that you consider relevant to the analysis (that is, have the potential to have a material impact on any conclusions reached based on the data and/or its analysis). | | | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please specify the item or issue, including a reference to the Technical Specifications or Template, and provide a description as well as rationale for its relevance to analysis. | | | | | |
| | Please describe in summary, but with sufficient detail to allow an assessment of materiality and potential impact. | | | | | |
| | Item name Reference | | Description and rationale | | | |
| | Insert text | Insert text | Insert text | | | |
| | (Add additional rows as necessary) | | | | | |



4 Perimeter of the ICS Calculation

| Template Sheets referred to in this section: | GAAP and ICS Balance Sheets |
|--|--|
| Key Technical Specification – Part 2 sections relevant to this section | 4. Reference ICS: Perimeter of the ICS Calculation |

| 9 | For the starting ICS balance sheet, did you encounter any difficulties splitting the insurance and non-insurance operations? | | | | | |
|----|---|---|--|--|--|--|
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please provide a description of issues that were encountered. | | | | | |
| | Amount | Description | | | | |
| | Insert text text | | | | | |
| | (Add additio | nal rows as necessary) | | | | |
| 10 | For the non-insurance portion of the ICS balance sheet, did you encounter any difficulties re-stating consolidated entities in your consolidated GAAP to a different basis of accounting (eg, joint ventures and joint operations)? | | | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | | | |
| | If YES, pleas | se provide a description of issues that were encountered. | | | | |
| | Amount | Description | | | | |
| | Insert text text | | | | | |
| | (Add additio | nal rows as necessary) | | | | |
| 11 | Has an amount been reported in the worksheet GAAP and ICS Balance Sheets, table Balance sheets, Row (-) adjustments already included in other equity items? | | | | | |



| | Provide your response by placing an 'x' in the relevant cell: | | | | | |
|----|--|------------------------|--|--|--|--|
| | YES | NO Not Applicable | | | | |
| | If YES, please provide a description of what was included in the amount in sufficient detail to understand why the offset was necessary. | | | | | |
| | Amount | Description | | | | |
| | Insert text | Insert text | | | | |
| | (Add addition | nal rows as necessary) | | | | |
| 12 | Has an amount been reported in the <i>Other</i> line in the <i>Equity</i> section of the worksheet <i>GAAP</i> and <i>ICS</i> Balance Sheets? | | | | | |
| | Provide your response by placing an 'x' in the relevant cell: | | | | | |
| | YES NO Not Applicable | | | | | |
| | If YES, please provide additional information on the amount so that the IAIS can determine whether that amount should be included within ICS capital resources. Amount Description Insert text (Add additional rows as necessary) | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |



5 Market-Adjusted Valuation

| MP Template Sheets referred to in this section: | GAAP and ICS Balance Sheets |
|---|---|
| Key MP Technical Specification – Part 2 sections relevant to this section | 5. Reference ICS: Market- Adjusted Valuation |

| 13 | Are there any type of products that qualify for the Middle Bucket, that do not qualify under ICS Version 2.0? If yes, please explain which types and why. Please specify the Current Estimates of these products under ICS Version 2.0 (in the General Bucket) and under the Candidate ICS as a PCR (in the Middle Bucket). | | | | | | | |
|--|---|------------------|-----------|----------------|------------|---------|---------------------------------------|-----------------------------------|
| Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | | | | | | |
| | | Type of product | Descrip | tion and ratio | nale | | Current Estimate in General Bucket | Current Estimate in Middle Bucket |
| | | Insert text | Insert te | ext | | | | |
| | | | | | | | | |
| | | (Add additional | rows as r | necessary) | | | | |
| 14 | \ \ | | | | non-life | premi | um liabilities applied? | |
| | | Provide your res | sponse b | y placing an | 'x' in the | e relev | rant cell: | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | | | | | |
| | If YES, please indicate which proxy was used and provide details on the difficulties faced in the calculation of non-life premium liabilities. Provide details on alternative proxies (including formulas) which the IAIS could consider (references/ links to external sources are also welcome). | | | | | | | |
| | | Item name | | Description | and ra | tionale | | |
| | | Insert text | | Insert text | | | | |
| | | | | | | | | |



| | (Add additional rows as n | ecessary) | | - |
|----|---|--|----------|------|
| 15 | Was the IAIS base yield curve methodology applied to any additional currency beyond the 35 for which the IAIS published data? | | | nich |
| | Provide your response b | y placing an 'x' in the relevant cell: | | |
| | YES NO Not Applicable | | | |
| | If YES, please describe a | ny difficulties experienced with the p | process. | |
| | Please describe in summa | ary. | | _ |
| | Item name | Description and rationale | | |
| | Insert text | Insert text | | |
| | | | | |
| | | | | |
| | (Add additional rows as n | ecessary) | | _ |
| | 6 Capital Requirem | ent | | |
| | Template Sheets referred to in this section: N/A | | | |
| | Key Technical Specification – Part 2 sections relevant to this section 7.3.4 Equity risk | | | |
| | | | | |
| 16 | Regarding the Neutral Adjusted Dampener (NAD) introduced for the calculation of the Equity risk charge, are regional calibrations needed to reflect market specificities? | | | (|
| | Provide your response by placing an 'x' in the relevant cell: | | | |
| | YES | NO Not Applicab | ole | |
| | | | | |



| Insert text | nsert text | |
|------------------------------------|-----------------------------|--------|
| | | |
| | | |
| | | |
| (Add additional rows as necessary) | | |
| | | |
| Self-assessment templ | ate for natural catastrophe | models |

| 17 | | of the scope of application erimeter of the natural catastrophe model's calculation. | |
|----|--|--|--|
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe the scope of application of the natural catastrophe model. | | |
| | Item name Description and rationale | | |
| | Insert text Insert text | | |
| | (Add additional rows as ne | ecessary) | |
| 18 | Do you have any natural catastrophe models that were developed internally? | | |



| | Provide your response by placing an 'x' in the relevant cell: | | | |
|----|--|---|--|--|
| | YES | NO Not Applicable | | |
| | | | | |
| | If YES, please describe the scope of application of each CAT model. | | | |
| | Item name | Description and rationale | | |
| | Insert text | Insert text | | |
| | | | | |
| | | | | |
| | (Add additional rows as ne | ecessary) | | |
| 19 | Safeguard 2 – Validation | | | |
| | The IAIG demonstrates that a rigorous process is in place by which they can establish whether their natural catastrophe model framework is sound or whether improvements are needed. | | | |
| | Is Safeguard 2 met? | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | |
| | | | | |
| | If YES, Please describe th | e validation process for the CAT model. | | |
| | Item name | Description and rationale | | |
| | Insert text | Insert text | | |
| | | | | |
| | | | | |
| | (Add additional rows as necessary) | | | |
| 20 | Safeguard 3 – Sign-off by senior management | | | |
| | | of the IAIG has ownership of the natural catastrophe model, and the model on process prescribed by the natural catastrophe model governance | | |
| | Is Safeguard 3 met? | | | |



| | Provide your response by placing an 'x' in the relevant cell: | |
|----|---|---|
| | YES | NO Not Applicable |
| | | |
| | If NO, please explain when | ther a change is planned and the expected timeline. |
| | Item name | Description and rationale |
| | Insert text | Insert text |
| | | |
| | | |
| | (Add additional rows as ne | ecessary) |
| 21 | Safeguard 4 – Statistical c | quality test |
| | The statistical quality test addresses issues related to the following technical aspects of the catastrophe model: • methodology and assumptions; • coverage of material risks; • data (including external data) and expert judgment; • aggregation of risks and diversification effects; • consistency with the method used for the calculation of technical provisions; • allowance for risk mitigation techniques and future management actions; and • financial guarantees and contractual options. Is Safeguard 4 met? | |
| | | y placing an 'x' in the relevant cell: |
| | YES | NO Not Applicable |
| | If YES, please describe in model. | summary how statistical quality tests are used in the natural catastrophe |
| | Item name | Description and rationale |
| | Insert text | Insert text |
| | | |
| | | |



| | (Add additional rows as necessary) | | |
|----|---|---------------------------|--|
| 22 | Safeguard 5 – Use test and governance The use test reflects the IAIG's view of its risks and is used in decision-making. Is Safeguard 5 met? | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe, in summary, how the use test is carried out, as well the model governance and internal controls at different stages of the model. | | |
| | Item name Description and rationale | | |
| | Insert text | Insert text | |
| | (Add additional rows as ne | ecessary) | |
| 23 | 23 Safeguard 6 – Documentation standards | | |
| | The documentation of the natural catastrophe model includes its use and other related aspects, such as: • facilitates the supervisory review of the model; • facilitates Senior Management's understanding; and • recognises the weaknesses of the model. Is Safeguard 6 met? | | |
| | Provide your response by placing an 'x' in the relevant cell: | | |
| | YES NO Not Applicable | | |
| | If YES, please describe, in summary, the documentation that is currently available. | | |
| | Item name | Description and rationale | |
| | Insert text | Insert text | |
| | | | |



| | (Add additional rows as necessary) | | |
|-----|---|-------------------------------------|--|
| 24 | Safeguard 7 – List of catastrophe risk sources that are not modelled | | |
| | The IAIG recognises the limitations in the scope of their natural catastrophe model. IAIGs make a list of natural catastrophe risks specified in the ICS but not modelled, and explain why those risks are not modelled. Is Safeguard 7 met? | | |
| | Provide your response b | y placing an 'x' in the relevant ce | ====================================== |
| | YES NO Not Applicable | | |
| | If YES, please list those natural catastrophe risks that are not modelled, the reason those risks are not modelled, and an assessment of the impact. | | |
| | Item name | Description and rationale | |
| | Insert text | Insert text | |
| | | | |
| | | | |
| | (Add additional rows as necessary) | | |
| | • | | |
| 6.3 | Non-insurance risk cl | harges | |
| T | Template Sheets referred to in this section: ICS Non-Insurance & Baseline | | |
| ı | Key Technical Specification – Part 2 sections relevant to this section 7.7 Non-Insurance Risk Charges | | |
| | | | |
| 25 | For the non-insurance entities reported as equity method investments (eg, joint ventures and joint operations) that are consolidated under GAAP, were there any reporting issues? | | |
| | Provide your response by placing an 'x' in the relevant cell: | | |
| | YES NO Not Applicable | | |



If YES, please describe the issue that you encountered.

| Item name | Reference | Description and rationale |
|-------------|-------------|---------------------------|
| Insert text | Insert text | |
| | | |
| | | |

(Add additional rows as necessary)



7 Additional Reporting

7.1 GAAP Plus

| Template Sheets referred to in this section: | ICS Summary.GAAP+ |
|--|--------------------------------|
| | ICS Balance Sheet.GAAP+ |
| | Financial Instruments.GAAP+ |
| | Tier 2 Non-Paid-Up |
| | ICS.GAAP+ > Insurance |
| | ICS > Non-Insurance & Baseline |
| Key Technical Specification – Part 1 sections relevant to this section | 9.1 GAAP Plus |

| 26 | Has an amount been reported in the worksheet ICS Balance Sheet.GAAP+, table Balance sheets, Row (-) adjustments already included in other equity items? | |
|--|--|------------------------|
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please provide a description of what was included in the amount in sufficient detail to understand why the offset was necessary. | |
| Amount Description Insert Insert text | | · |
| | (Add addition | nal rows as necessary) |
| 27 | Has an amount been reported in the <i>Other</i> line in the <i>Equity</i> section of the worksheet <i>ICS Balance Sheet.GAAP</i> +? | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | |



| | If YES, please provide additional information on the amount so that the IAIS can determine whether that amount should be included within ICS capital resources. | | |
|----|--|---------------------|--------------------------|
| | Amount | Description | |
| | Insert text | | |
| | (Add additional rows | as necessary) | |
| 28 | Were any material reclassifications made between reported general purpose audited financial statements (GAAP) and GAAP Plus in <i>ICS Balance Sheet</i> .GAAP+ (table <i>Balance sheets</i> , Column [7] <i>Reclassification from GAAP</i>)? | | |
| | Provide your respor | se by placing an ' | x' in the relevant cell: |
| | YES | NO | Not Applicable |
| | If YES, please describe the reclassifications made between reported GAAP and GAAF Plus. Reclassifications may include, for example, any amounts that are adjusted due to changes in balance sheet presentation, netting or grossing of balances, differences in the scope of the group, or application of different consolidation methods or rules. | | |
| | Item name | Description and | d rationale |
| | Insert text | Insert text | |
| | | | |
| | (Add additional rows | as necessary) | |
| 29 | Did you conclude that the reference ICS and GAAP Plus are materially the same (and hence you did not prepare a separate GAAP Plus balance sheet with explicit adjustments)? | | |
| | Provide your respor | se by placing an 'x | x' in the relevant cell: |
| | YES | NO | Not Applicable |



| | If YES, please describe the analyses performed to determine that the balances up GAAP Plus did not materially differ from the reference ICS, and specify the key fas support of that determination. Please describe in summary, but with sufficient detail to allow an assessment of materiality and direction of impact. | |
|----|--|--|
| | Item name | Description and rationale |
| | Insert text | Insert text |
| | | |
| | (Add additional rows as ne | ecessary) |
| 30 | Were any GAAP Plus special calculating the GAAP Plus | cifications not followed or simplifying assumptions made in Balance Sheet? |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe, for each GAAP Plus specification not followed and each simplifying assumption made, the impact of using such alternative treatment (from the specifications, or simplification) particularly if this may not be justifiable using the proportionality principle. Please provide your rationale for the approach taken. Please describe in summary, but with sufficient detail to allow an assessment of materiality and direction of impact. | |
| | | |
| | Item name | Description and rationale |
| | Insert text | Insert text |
| | | |
| | (Add additional rows as ne | ecessary) |
| 31 | U.S. GAAP Plus – Were t Plus? | here any difficulties encountered when applying US GAAP |



| | Provide your response by placing an 'x' in the relevant cell: | | | |
|-----------------------------|--|--|---|--|
| | YES | NO Not Applicable | | |
| | | | | |
| | = - | in summary, but with sufficient detail to allow an assessment of impact. Please list in order of difficulty. | İ | |
| | Item Reference | Response | | |
| | Insert text | Insert text | | |
| | | | | |
| | | | | |
| | (Add additional rows as | necessary) | | |
| 32 | IFRS GAAP Plus – Wer | e balances reported under the IFRS GAAP Plus approach? | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | |
| | Explain what prevented you from reporting the data this year. Would these issues or limitations be resolved before next year? If not, when woul you expect them to be resolved? Are there any simplifying assumptions or practical expedients that could b applied in future Field Testing that would address these issues or limitations? | | | |
| Question Reference Response | | | | |
| | Insert text | Insert text | | |
| | 1. | | | |
| | 2. | | | |
| | 3. | | | |
| | (Add additional rows as necessary) | | | |



| 33 | IFRS GAAP Plus – If you are an IFRS reporter (regardless of whether you reported under IFRS GAAP Plus for this year's Field Testing) or have not answered these questions in previous years, please review the technical specifications presenting the IFRS GAAP Plus approach. Do you foresee any difficulties that you could encounter if you were to apply this approach to create an IFRS GAAP Plus balance sheet? | | | | |
|----|---|-----------------------------------|--|--|--|
| | Provide your response by placing an 'x' in the relevant cell: | | | | |
| | If YES, please provide details of any anticipated difficulties in applying this approach and any solutions that you can propose. | | | | |
| | | | | | |
| | Difficulty identified | Explanation and proposed solution | | | |
| | Insert text | | | | |
| | | | | | |
| | (Add additional rows as necessary) | | | | |
| 34 | IFRS GAAP Plus – Have you developed a methodology for calculating a discount rate or curve for purposes of implementing IFRS 17 under IFRS GAAP Plus? | | | | |



| Provide your response | by placing an 'x' in the relevant cell: | |
|---|---|--|
| YES | NO Not Applicable | |
| | | |
| | | |
| If YES, please describe | your current thinking on this methodology including: | |
| Did you use multiple curves/rates? If so please describe how these will be applied and how they might differ. Did you apply a top-down or bottom-up method to develop a discount rate/curver. If top-down, describe how the yield curve that reflects the current market rates return implicit in the fair value measurement of a reference portfolio of assets was or may be determined, as well as other relevant considerations requiring judgmen (e.g. what was or may be used as the reference portfolio, how a risk premium are expected default were or may be calculated and deducted). If bottom-up, describe relevant considerations requiring judgement such as how liquidity premium were or may be calculated and how the risk-free rate/curve was or may be, constructed. What was considered to be the observable period (last liquid point)? Did you use a spot rate or a forward rate for the ultimate rate? How is that rate determined? When does it begin to apply? Describe the technique that was used, if any, to extrapolate between the last liquid point and the ultimate rate. How did or how might the discount curve construction differ by currency? | | |
| <u> </u> | ner adjustments that were, or may be, made. | |
| Question Reference | Response | |
| Insert text | Insert text | |
| 1. | | |
| 2. | | |
| (Add additional rows as | s necessary) | |
| | discussion of what elements are being considered and the on a discounting methodology | |
| | | |
| | | |
| | | |
| | | |
| | | |



| 35 | IFRS GAAP Plus – Have you developed a methodology for calculating a risk adjustment for purposes of implementing IFRS 17? | | | | |
|----|---|-------------------|--|--|--|
| | Provide your response by placing an 'x' in the relevant cell: | | | | |
| | YES | NO Not Applicable | | | |
| | If YES, please describe your methodology including: | | | | |
| | What method was used (eg VaR, TVaR, Cost of Capital) and what is the rationale choosing this method? What time period was used and what is the rationale for choosing that time period What risks were captured in your non-financial risks? What level of aggregation was used? How was reinsurance applied or addressed? Did you incorporate a diversification effect? If so, please describe. How did you determine your confidence level to develop a risk adjustment and was the level? How did the risk adjustment differ from the MOCE defined in the reference ICS? For those products for which you used the Premium Allocation Approach, described in the risk adjustment would be calculated. | | | | |
| | Question Reference | Response | | | |
| | Insert text | Insert text | | | |
| 1. | | | | | |
| | 2. | | | | |
| | (Add additional rows as necessary) | | | | |
| 36 | IFRS GAAP Plus – Have you developed a policy for determining portfolio allocation for purposes of implementing IFRS 17? | | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | | |
| | If YES, Please describe this methodology including: 1. Is the portfolio allocation under IFRS 17 more or less granular than the ICS segments? Please describe any material differences. | | | | |
| | Question Reference | Response | | | |



| | Insert text | Insert text | | |
|----|--|---|--|--|
| | 1. | | | |
| | (Add additional rows as r | necessary) | | |
| | If NO, please provide a discussion of what you are currently considering and the time for concluding on assigning/defining portfolios. | | | |
| | | | | |
| | | | | |
| 37 | IFRS GAAP Plus – Did you apply the Premium Allocation Approach (PAA) to any products? | | | |
| | If you applied the PAA to | any life products, please indicate this separately. | | |
| | Provide your response | by placing an 'x' in the relevant cell: | | |
| | YES | NO Not Applicable | | |
| | If YES, please indicate what portion of liabilities were reported on an undiscounted bas on the GAAP Plus Balance Sheet. | | | |
| | Item name | Reported amount | | |
| | Insert text | Insert text | | |
| | | | | |
| | | | | |
| | (Add additional rows as r | necessary) | | |
| 38 | IFRS GAAP Plus – Did you apply the PAA to any contracts with a coverage period greater than one year? | | | |
| | Provide your response | by placing an 'x' in the relevant cell: | | |
| | YES | NO Not Applicable | | |
| | If YES, please describe t | he products and the rationale for applying the PAA. | | |



| | Item name Description and rationale | | | ionale |
|----|---|----------------------|--------|---|
| | Insert text | Insert text | | |
| | | | | |
| | | | | |
| | (Add additional rows as | necessary) | | |
| 39 | AOCI adjustment – Did you have any difficulties in applying the AOCI adjustment, if applicable? | | | |
| | Provide your response | e by placing an 'x | ' in t | he relevant cell: |
| | YES | NO | | Not Applicable |
| | If YES, can you exp Do you have any s technical specificati (Add additional rows as | uggestions that ons? | | e difficulty? d help to resolve the difficulty or clarify the |
| | Question Reference | Response | | |
| | Insert text | Insert text | | |
| | 1. | | | |
| | 2. | | | |
| | If NO, please explain w | ny this segregati | on w | as not performed. |
| | | | | |
| 40 | Do you have any suggested improvements or refinements to the IFRS GAAP Plus Technical Specifications? | | | r refinements to the IFRS GAAP Plus |
| | Provide your response | e by placing an 'x | ' in t | he relevant cell: |
| | YES | NO | | Not Applicable |



| Please describe in summary, but with sufficient detail to allow an assessment of materiality and potential impact. | | | | |
|---|--|--|--|--|
| Item name | Description and ratio | nale | | |
| Insert text | Insert text | | | |
| | | | | |
| (Add additional rov | vs as necessary) | | | |
| Where appropriate, this includes comments on data, additional relevant data, and/or calculations that you consider relevant to the Field Testing analysis (that is, have the potential to have a material impact on any conclusions reached based on the data and/or its analysis). Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please specify the item or issue, including a reference to the Technical Specifications or Template, and provide a description as well as rationale for its relevance to the Field Testing analysis. Please describe in summary, but with sufficient detail to allow an assessment of | | | | |
| relevance to the Fi Please describe in | eld Testing analysis. summary, but with suffic | ient detail to allow an assessment of | | |
| relevance to the Fi | eld Testing analysis. summary, but with suffic | ient detail to allow an assessment of Description and rationale | | |



7.1.1 Reconcilations

Reconciliations: Life Insurance Liabilities - GAAP Plus to MAV

| Template Sheets referred to in this section: | ICS Balance Sheet.GAAP+ |
|---|-------------------------|
| Key Technical Specification sections relevant to this section | 9.1 GAAP Plus |
| | |

| 42 | Reconciliation of life insurance liabilities GAAP Plus to MAV includes two user- defined columns to report any material adjustments required to move from GAAP Plus to MAV excluding changes to contract boundaries, cash flow projections and discounting. Were these columns utilised? | | | | |
|----|---|---|--|--|--|
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | | |
| | If YES, please provide column. | e a description for the adjustment amounts reported in each | | | |
| | Item name | Description and rationale | | | |
| | Insert text | Insert text | | | |
| | | | | | |
| | | | | | |
| | (Add additional rows a | Add additional rows as necessary) | | | |
| 43 | Reconciliation of life insurance liabilities GAAP Plus to MAV includes a column labelled <i>other</i> to report any additional adjustments required to move from GAAP Plus to MAV excluding changes explicitly reported in previous columns. Was this column utilised? | | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | | |
| | If YES, please provide | e a description for the amounts reported. | | | |
| | Item name | Description and rationale | | | |



| | Insert text | Insert text | | | |
|--------|--|----------------------------|--------|-------------------------|---|
| | | | | | |
| | | | | | |
| | (Add additional rows as | s necessary) | | | |
| 44 | Do you have further comments regarding this section? | | | | |
| | Where appropriate, this includes comments on data, additional relevant data, and/or calculations that you consider relevant to the analysis (that is, have the potential to have a material impact on any conclusions reached based on the data and/or its analysis). | | | r | |
| | Provide your respons | e by placing an 'x' in the | relev | ant cell: | |
| | YES | NO No | ot Ap | pplicable | |
| | If YES, please specify the item or issue, including a reference to the Technical Specifications or Template, and provide a description as well as rationale for its relevance to the analysis. Please describe in summary, but with sufficient detail to allow an assessment of materiality and potential impact. | | | | |
| | Item name | Reference | Des | scription and rationale | |
| | Insert text | Insert text | | | |
| | | | | | |
| | | | | | |
| | (Add additional rows as | s necessary) | | | |
| | Reconciliations: Non-Life Insurance Liabilities - GAAP Plus to MAV | | | | |
| Templ | Template Sheets referred to in this section: ICS Balance Sheet.GAAP+ | | | | |
| Key Te | Key Technical Specification sections relevant to this section 9.1 GAAP Plus | | | | |
| | | | | | _ |
| 45 | Did you report any amor reconciliations? | unt in the Other columns | for th | ne premium liability | |



| | Provide your response by placing an 'x' in the relevant cell: | | | |
|----|---|-----------------------------|------------------------------------|--|
| | YES | NO | Not Applicable | |
| | | | | |
| | If YES, please describe all the amounts reported as part of <i>Other</i> in each table, provide the rationale supporting your adjustments, and indicate the impact of adopting your adjustments. | | | |
| | Please describe in summary, but with sufficient detail to allow an assessment of materiality (Please express the amounts as a % of Total Assets) and direction of impact. | | | |
| | Table | Item name | Description and rationale | |
| | GAAP to MAV | Insert text | Insert text | |
| | GAAP to GAAP Plus | | | |
| | GAAP Plus to MAV | | | |
| | (Add additional r | rows as necessary) | | |
| 46 | Do you have any | y other comments on the p | premium liability reconciliations? | |
| | Where appropriate, this includes comment on data, additional relevant data, and/or calculation that you provide which you consider relevant to the analysis (that is, have the potential to have a material impact on any conclusions reached based on the data and/or its analysis). | | | |
| | Provide your re | esponse by placing an 'x' i | n the relevant cell: | |
| | YES | NO | Not Applicable | |
| | If YES, please specify the item or issue and discuss it and the rationale for its relevance to the analysis. Please describe in summary, but with sufficient detail to allow an assessment of materiality and potential impact. | | | |
| | | | | |
| | Item name | Description and ra | tionale | |
| | Insert text | Insert text | | |
| | | | | |
| | | | | |
| | | | | |



| | (Add additional rows as necessary) | | | |
|----|--|----------------------------|---|--|
| 47 | Did you report any amounts in the Other columns for the claim liability reconciliation? | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe all the amounts reported as part of <i>Other</i> in each table, provide the rationale supporting your adjustments, and indicate the impact of adopting your adjustments. | | | |
| | | | | |
| | | | icient detail to allow an assessment of s a % of Total Assets) and direction of | |
| | Table | Item name | Description and rationale | |
| | GAAP to GAAP Plus | Insert text | Insert text | |
| | GAAP Plus to MAV | | | |
| | (Add additional re | ows as necessary) | | |
| 48 | Do you have furth | ner comments regarding | this section? | |
| | Where appropriate, this includes comments on data, additional relevant data, and/or calculations that you consider relevant to the analysis (that is, have the potential to have a material impact on any conclusions reached based on the data and/or its analysis). | | | |
| | Provide your re | sponse by placing an 'x' i | n the relevant cell: | |
| | YES | NO | Not Applicable | |
| | If YES, please specify the item or issue, including a reference to the Technical Specifications or Template, and provide a description as well as rationale for its relevance to the analysis. | | | |
| | Please describe i | <u> </u> | icient detail to allow an assessment of | |
| | Item name | Reference | Description and rationale | |
| | Insert text | Insert text | | |



| (Add additional rows as necessary) | | | |
|------------------------------------|--|--|--|



8 Internal Models

| Template Sheets referred to in this section: | ICS Other Methods |
|---|---------------------|
| Key MP Technical Specification – Part 2 sections relevant to this section | 9.2 Internal Models |

The purpose of this section is to enable IAIGs to provide supplementary qualitative information (with respect to the quantitative data submission) to support the assessment of the appropriateness of the use of internal models for the reference ICS. This will facilitate a better understanding of:

- a. The reasons for differences in outcomes between the ICS standard method and risk charges determined by internal models at the same calibration level; and
- b. The nature and scope of application of internal models used by IAIGs

| 49 | Do any of the risk charges calculated using a VaR 99.5% over a one-year time horizon (in 9.2 Other methods) differ materially from the equivalent ICS risk charges determined according to the ICS standard method? | | |
|----|---|---|--|
| | | y placing an 'x' in the relevant cell: NO Not Applicable | |
| | If YES, please quantify and outline the key drivers of any material differences for each risk. Please also outline any material differences in your definition of each risk compared to that used by the IAIS. | | |
| | Please describe in summary, but with sufficient detail to allow an assessment of materiality and direction of impact. | | |
| | Risk | Key drivers of differences between IAIG's reported capital amounts for regulatory purposes and ICS standard method risk charges. Please also include outline of any material differences in the definitions of risks. | |
| | Mortality risk | Insert text | |
| | Longevity risk | | |
| | Morbidity/Disability risk | | |
| | Lapse risk | | |



| | Expense risk | | | |
|----|----------------------------|--|--|--|
| | Premium risk | | | |
| | Claims reserve risk | | | |
| | Catastrophe risk | | | |
| | Interest Rate risk | | | |
| | Non-default Spread risk | | | |
| | Equity risk | | | |
| | Real Estate risk | | | |
| | Currency risk | | | |
| | Asset Concentration risk | | | |
| | Credit risk | | | |
| | Operational risk | | | |
| | (Add additional rows as ne | ecessary) | | |
| 50 | Did you report other risks | Did you report other risks not captured by the ICS? | | |
| | Provide your response by | y placing an 'x' in the relevant cell: | | |
| | YES | NO Not Applicable | | |
| | | ose risks and the materiality of each risk if more than one risk is e provide the rationale for modelling these risks. | | |
| | Risk name | Description and rationale | | |
| | Insert text | Insert text | | |
| | | | | |
| | | | | |
| | (Add additional rows as ne | ecessary) | | |



| 51 | Does the ICS standard method cover risks that are not included in your internal economic capital model(s)? | | |
|----|--|---|--|
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please explain why those risks are not explicitly modelled, and how this is addressed. Please describe in summary, but with sufficient detail to allow an assessment of materiality and direction of impact. | | |
| | Risk name | Description and rationale of why the risk is not modelled | |
| | Insert text | Insert text | |
| | (Add additional rows as ne | ecessary) | |
| 52 | For the actual internal model results where the risk measure and/or confidence interval differ from 99.5% VaR over a one-year time horizon, please detail the reasons why a different target calibration is used and outline any adjustments used when providing data at 99.5% VaR over a one-year time horizon. | | |
| | Please describe in summary, but with sufficient detail to allow an assessment of materiality and direction of impact. | | |
| | Item where different from ICS calibration | Reasons and adjustments when providing data using same calibration as ICS | |
| | Insert text | Insert text | |
| | (Add additional rows as ne | ecessary) | |
| 53 | Where you have indicated the results come from a model whose use has been approved by a supervisory authority, please provide details and scope of the approval – has the approval been granted by the group-wide supervisor, a single legal entity supervisor or a supervisory college? | | |
| | | | |



| | Model approved | Details of the approval | |
|----|--|---|--|
| | Insert text | Insert text | |
| | | | |
| | | | |
| | (Add additional rows as ne | ecessary) | |
| 54 | - | ication benefits in worksheet 9.2 Other methods and demonstrate that it d to provide a short description of the dependency modelling. | |
| | | | |
| | Difference | Description of difference | |
| | Insert text | Insert text | |
| | | | |
| | | | |
| | (Add additional rows as ne | ecessary) | |
| 55 | Considering the risk profile of your group, is there any area for which the ICS standard method does not appropriately capture the risk profile of your group and for which an internal economic capital modelling approach would be more appropriate? | | |
| | Provide your response by placing an 'x' in the relevant cell: | | |
| | YES NO Not Applicable | | |
| | | | |
| | If YES, please describe why an internal economic capital modelling approach would capture your risk profile more appropriately in the context of a consistent assessment of risk needed for the ICS. | | |
| | Item name | Description and rationale | |
| | Insert text | Insert text | |
| | | | |
| | | | |
| | (Add additional rows as necessary) | | |



9 Self-assessment Template for Internal Models

IAIGs participating in the additional reporting for internal models should complete and submit the self-assessment template, which assesses the degree of compliance with the list of prerequisites.

The scope of application of internal models is limited to the calculation of the ICS capital requirement and not to other areas of the ICS such as capital resources or valuation (eg MAV). Therefore, the development of internal models is meant to introduce only an alternative calculation of the ICS capital requirement, while the valuation of the assets and liabilities of the IAIG would continue to be calculated according to the methods set out by the IAIS. However, the IAIS expects convergence between the valuation basis embedded in the internal model and the valuation basis for the ICS during the monitoring period.

| IM1 | Do you use a full internal model? | | |
|-----|--|---|--|
| | Provide your response by placing an 'x' in the relevant cell: | | |
| | YES NO Not Applicable | | |
| | If No, please describe which type of partial internal model you use. | | |
| | Please describe in summa internal model. | ry, but with sufficient detail to allow an assessment of the perimeter of the | |
| | Partial model type | Description | |
| | Partial – One or more risk charges of the ICS standard method capital requirement | Insert text if this partial model type is used | |
| | Partial – One or more sub-risk charges of the ICS standard method capital requirement | Insert text if this partial model type is used | |
| | Partial – One or more risk charges or sub-risk charges not captured by the ICS standard method capital requirement | Insert text if this partial model type is used | |



| | Partial –Only one or more major business units or legal entities | Insert text if this partial model type is used | |
|-----|--|---|--|
| | Other model structure | Insert text if this partial model type is used | |
| | (Add additional rows as ned | cessary) | |
| IM2 | Do you use the partial internal model for calculation of risk charges in any of the below mentioned risk categories? | | |
| | Provide your response by | placing an 'x' in the relevant cell: | |
| | YES | Not Applicable | |
| | If YES, please describe in s below mentioned risk categ | summary, how the internal model is used to calculate risk charges in ories. | |
| | Risk category | Description of the usage | |
| | Mortality risk | | |
| | Longevity risk | | |
| | Morbidity/Disability risk | | |
| | Lapse risk | | |
| | Expense risk | | |
| | Premium risk | | |
| | Claims reserve risk | | |
| | Catastrophe risk | | |
| | Interest Rate risk | | |
| | Non-default Spread risk | | |
| | Equity risk | | |
| | Real Estate risk | | |
| | Currency risk | | |



| | Asset Concentrat | tion risk | | | |
|-----|---|-------------------|---------------|-------------------|--------------|
| | Credit risk | | | | |
| | Operational risk | | | | |
| | (Add additional row | s as necessar | /) | | |
| IM3 | Do you meet the cri | teria for valida | tion? | | |
| | Provide your response | onse by placin | g an 'x' in t | he relevant cell: | |
| | YES | NO | | Not Applicable | |
| | | | | | |
| | If Yes, please descr | | - | | |
| | If No, please descri | be the shortco | mings and | whether changes | are planned. |
| | Description item | Description r | ationale | | Yes/No |
| | Insert text | Insert text | | | |
| | | | | | |
| | | | | | |
| | (Add additional row | s as necessar | /) | | |
| IM4 | Do you meet the cri | teria for statist | ical quality | tests? | |
| | Provide your response | onse by placin | g an 'x' in t | he relevant cell: | |
| | YES | NO | | Not Applicable | |
| | | | | • | |
| | If YES, please describe in summary on how statistical quality tests are used in the internal model. | | | | |
| | If No, please describe the shortcomings and whether changes are planned. | | | | |
| | Comment name | Comment de | scription | | Yes/No |
| | Insert text | Insert text | | | |
| | | | | _ | |
| | | | | | |



| | (Add additional rows as necessary) | | | |
|-----|--|--|--------|--|
| IM5 | Do you meet the criteria for calibration tests? | | | |
| | YES If YES, please desc | YES, please describe in summary on how calibration tests are used in the internal model. | | |
| | Statistical quality test | be the shortcomings and whether changes Description of the test | Yes/No | |
| | Insert text | Insert text | | |
| | (Add additional row | (s as necessary) | | |
| IM6 | • | iteria for the use test? | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable Please describe in summary the areas where expert judgement is predominantly used. | | | |
| | (Add additional row | rs as necessary) | | |
| IM7 | Are the criteria for the use test met? | | | |



| YES [| NO Not Applicable | | |
|---|---|--------------------------------------|--|
| | ibe in summary, how the use test is met. e the shortcomings and whether changes a | are planned. | |
| Use test | Description | Yes/No | |
| Business planning | Insert text | | |
| Mergers and Acquisitions | | | |
| Reinsurance | | | |
| Investment | | | |
| Underwriting | | | |
| Risk Management | | | |
| Capital Management (assessment and allocation) | | | |
| Performance Management | | | |
| (Add additional rows | as necessary) | | |
| Are the criteria for mo | Are the criteria for model governance met? | | |
| Provide your response by placing an 'x' in the relevant cell: | | | |
| YES | NO Not Applicable | | |
| If YES, please descri of the model. | ibe in summary the model governance and | internal controls at different stage | |
| If No, please describ | e the shortcomings and whether changes a | are planned. | |



| | Model stage | Description | Yes/No |
|------|--|------------------------------|--------|
| | Model development | Insert text | |
| | Model deployment | | |
| | Model implementation | | |
| | Model usage | | |
| | Model validation | | |
| | Model changes | | |
| | Data quality | | |
| | Use test checking | | |
| | Roles and relationships of | | |
| IM9 | Are the criteria for the | documentation standards met? | |
| | Provide your response by placing an 'x' in the relevant cell: | | |
| | YES NO Not Applicable If YES, please describe in summary how the standards are met. | | |
| | | | |
| | If No, please describe | re planned. | |
| | Documentation type | Description | Yes/No |
| | Insert text | Insert text | |
| | | | |
| | | | |
| | (Add additional rows as necessary) | | |
| IM10 | Please describe the model documentation process at different stages of the model. | | |



| Model stage | Description |
|--|-------------|
| Model development | Insert text |
| Model deployment | |
| Model implementation | |
| Model usage | |
| Model validation | |
| Model changes | |
| Data quality | |
| Use test checking | |
| Roles and relationships of units responsible for documentation | |



10 Economic impact assessment

As part of the agreement for the ICS to enter the monitoring period, the IAIS committed¹ to producing an Economic Impact Assessment of the ICS ahead of its implementation as a Prescribed Capital Requirement (PCR) in 2025.

The purpose of the assessment is to develop an understanding of any potential significant effects of implementation of the ICS, which could be positive or negative. The assessment will consider issues across different regions and could cover a broad range of potential impacts, such as those that might affect the market operations of insurers, the financial markets or the availability of insurance products.

Impact on product availability

One of the main concerns expressed during discussions with Members and stakeholders is the potential for the ICS to have a negative impact on the functioning of insurance markets and restrict the availability of certain types of long-term insurance products in certain regions or markets.

| EIA1 | Do you foresee the implementation of the ICS having an impact on the long-term strategy of your business? | | |
|----------|--|------------------------|--|
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe in sufficient detail the key areas of your strategy that might affected. | | |
| | Impact | Description | |
| | Insert text | Insert text | |
| | (Add additio | nal rows as necessary) | |
| EIA 2 | Do you foresee the implementation of the ICS having an impact on your new business strategy? | | |
| | Provide your response by placing an 'x' in the relevant cell: | | |
| | YES | NO Not Applicable | |

¹ . Explanatory Note on the ICS and Comparability Assessment 14 November 2019. <u>191120-Explanatory-Note-on-the-ICS.pdf (iaisweb.org)</u>



| | If YES, please describe in sufficient detail the key areas of your new business strategy that might affected. | | | | | |
|----------|--|------------------------------------|--|--|--|--|
| | Description | | | | | |
| | Insert text | Insert text | | | | |
| | (Add additio | (Add additional rows as necessary) | | | | |
| EIA 3 | Do you foresee the introduction of the ICS having a significant impact on the pricing of products? | | | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe those impacts in sufficient detail. | | | | | |
| | Impact | Description | | | | |
| | Insert text | Insert text | | | | |
| | (Add additional rows as necessary) | | | | | |
| EIA 4 | Do you foresee the introduction of the ICS having a significant impact on the range of product features available in the market (for example investment guarantees)? | | | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | | | |
| | If YES, please describe those impacts in sufficient detail. | | | | | |
| | Impact | Description | | | | |
| | Insert text | Insert text | | | | |



| | (Add additional rows as necessary) | | |
|----------|---|---|--|
| EIA 5 | Do you foresee the introduction of the ICS having a significant impact on the duration of products written (eg offering products with shorter-term guarantees)? | | |
| | Provide yo | our response by placing an 'x' in the relevant cell: | |
| | YES | NO Not Applicable | |
| | If YES, plea | se describe those impacts in sufficient detail. | |
| | Impact | Description | |
| | Insert text | Insert text | |
| | (Add ad | ditional rows as necessary) | |
| EIA 6 | Do you forestypes of pro | see the introduction of the ICS resulting in your withdrawal from writing specific ducts? | |
| | Provide yo | our response by placing an 'x' in the relevant cell: | |
| | YES NO Not Applicable | | |
| | If YES, please describe in sufficient detail. | | |
| | Impact | Description | |
| | Insert text | Insert text | |
| | (Add additional rows as necessary) | | |
| EIA 7 | Do you foresee the implementation of the ICS requiring changes to your risk appetite or your approach to risk mitigation? | | |
| | Provide yo | ur response by placing an 'x' in the relevant cell: | |
| | YES NO Not Applicable | | |
| | | | |



| | If YES, please describe those changes in sufficient detail. | | | |
|----------|---|--|--|--|
| | _ | | | |
| | Impact | Description | | |
| | Insert text | | | |
| | | | | |
| | (Add additional rows a | as necessary) | | |
| EIA 8 | Do you foresee any circumstances in which the introduction of the ICS might create or help resolve protection gaps in your region (eg due to reduced product availability)? | | | |
| | Provide your respon | se by placing an 'x' in the relevant cell: | | |
| | YES | NO Not Applicable | | |
| | If YES, please describe the impacts in sufficient detail. | | | |
| | Impact | Description | | |
| | Insert text | | | |
| | | | | |
| | (Add additional rows a | as necessary) | | |
| EIA 9 | Would you expect any reduction in your product availability to be filled by other market participants? | | | |
| | Provide your respon | se by placing an 'x' in the relevant cell: | | |
| | YES | NO Not Applicable | | |
| | Please describe in sufficient detail any impacts on product availability in your region. | | | |
| | Impact | Description | | |
| | Insert text | | | |
| | | | | |



| (A. I.I. a. I.P.C. a. I. a. |
|---|
| (Add additional rows as necessary) |
| |

Impact on insurers' business models

The ICS is not intended to result in an increase in overall capital requirements however the implementation of the ICS might result in changes to the capital position and risk sensitivity for some IAIG's. This could result in changes to an IAIG's business model and impact the profitability of some of its products, business units, or legal entities.

| EIA 10 | Do you anticipate that the implementation of the ICS could lead to a significant change in your solvency position? | | | |
|------------------------------------|---|------------------------|--|--|
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe those changes in sufficient detail. | | | |
| | Impact | Description | | |
| | Insert text | Insert text | | |
| | (Add additio | nal rows as necessary) | | |
| EIA 11 | Do you anticipate that the implementation of the ICS could lead to a significant change in the risk sensitivity of your solvency position? | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe those changes in sufficient detail. | | | |
| | Impact Description | | | |
| | Insert text | | | |
| (Add additional rows as necessary) | | | | |



| EIA 12 | Do you anticipate that the implementation of the ICS could lead to a significant change in the profitability of any business units or entities within your business? | | | | |
|-----------|---|---|--|--|--|
| | Provide your response by placing an 'x' in the relevant cell: | | | | |
| | YES | NO Not Applicable | | | |
| | If YES, please describe the drivers of profitability that might be affected in sufficient detail. | | | | |
| | Impact | Description | | | |
| | Insert text | Insert text | | | |
| | (Add addition | nal rows as necessary) | | | |
| EIA 13 | Do you anticipate circumstances in which you would need to raise additional capital (beyond your current expectations) as a result of the implementation of the ICS? | | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe those key factors that are most likely to cause you to raise additional capital in sufficient detail. | | | | |
| | Impact | Description | | | |
| | Insert text | Insert text | | | |
| | (Add addition | nal rows as necessary) | | | |
| EIA 14 | Do you have any concerns over your ability to raise capital or issue debt in the future as a result of the implementation of the ICS? | | | | |
| | Provide you | ur response by placing an 'x' in the relevant cell: NO Not Applicable | | | |



| | If YES, please describe the key factors affecting your ability to raise capital or issue debt in sufficient detail. | | | | ebt in | |
|-----------|---|------------|--|---------|--|-----------|
| | Impact | Descript | ion | | | |
| | Insert text | Insert te | xt | | | |
| | (Add additio | nal rows a | as necessary) | | | |
| EIA 15 | Do you foresee any circumstances in which you might significantly change to your risk management strategy as a result of the introduction of the ICS? | | | k | | |
| | Provide yo | ur respon | se by placing an ' | x' in t | he relevant cell: | |
| | YES | | NO | | Not Applicable | |
| | If YES, please describe those changes in sufficient detail. | | | | | |
| | Impact | | Description | | | |
| | Insert text | | | | | |
| | (Add additio | nal rows a | as necessary) | | | l |
| EIA 16 | _ | - | rcumstances in w sult of the introduc | | you might significantly change your approof the ICS? | each to |
| | Provide yo | ur respon | se by placing an ' | x' in t | he relevant cell: | |
| | YES | | NO | | Not Applicable | |
| | | | e those key facto lerivatives or othe | | sufficient detail. For example would you eliging strategies? | expect to |
| | Impact | | Description | | | |
| | Insert text | | | | | |



| | (Add additional rows a | as necessary) |
|-----------|--|--|
| EIA 17 | • | nstances in which you might significantly change your investment be implementation of the ICS? |
| | Provide your respon | se by placing an 'x' in the relevant cell: |
| | YES | NO Not Applicable |
| | If YES, please describ | pe those changes in sufficient detail. |
| | Impact | Description |
| | Insert text | |
| | | |
| | (Add additional rows a | as necessary) |
| EIA 18 | Do you foresee circum as a result of the intro | nstances in which you might significantly change your group structure duction of the ICS? |
| | Provide your respon | se by placing an 'x' in the relevant cell: NO Not Applicable |
| | If YES, please describ | be those changes in sufficient detail. |
| | Impact | Description |
| | Insert text | |
| | | |
| | (Add additional rows a | as necessary) |
| EIA 19 | Do you foresee any of the ICS? | ther changes to your operating model as a result of the introduction of |
| | Provide your respon | se by placing an 'x' in the relevant cell: |



| | | YES | | NO | | Not Applicable | |
|-----------|--|-------------------------------------|-------|-------------------|----------------|--|----|
| | If YES, please describe those changs in sufficient detail. | | | | icient detail. | | |
| | Imp | pact | С | escription | | | |
| | Ins | ert text | | | | | |
| | | | | | | | |
| | (Add | l additional rows | as | necessary) | | | |
| EIA 20 | _ | ou foresee any duction of the IC | _ | ificant improver | nents | s in your ability to manage risk as a result of th | ıe |
| | Pro | vide your respo | nse | by placing an '› | c' in t | he relevant cell: | |
| | | YES | | NO | | Not Applicable | |
| | If YE | S, please descr | ibe 1 | those improvem | nents | in sufficient detail. | |
| | Imp | pact | С | escription | | | |
| | Ins | ert text | | | | | |
| | | | | | | | |
| | (Ada | l additional rows | as | necessary) | | | |
| EIA 21 | Do y | = | sign | ificant benefits | to yo | ur business as a result of the introduction of th | ne |
| | Pro | vide your respo | nse | by placing an '› | c' in t | he relevant cell: | |
| | | YES | | NO | | Not Applicable | |
| | If YE | S, please descr | ibe 1 | those benefits in | n suf | ficient detail. | |
| | Imp | pact | С | escription | | | |



| Insert text | | |
|------------------------|---------------|---|
| | | |
| (Add additional rows a | as necessary) | • |

Impact on financial markets

An area of concern raised by both member and stakeholders is the potential impact of the ICS on investment markets and the ICS being a driver of pro-cyclicality in broader financial markets. The risk to be assessed is whether the ICS might lead to convergence of investment strategies of IAIGs to a limited pool of assets whose prices movements might then be magnified under specific investment conditions. The concern is that this concentration of exposure has the potential to lead some pro-cyclicality in the broader financial markets.

| EIA 22 | - | Do you foresee potential for changes in investment strategy across the insurance industry which lead to greater pro-cyclical behaviour, as a result of the implementation of the ICS? | | | | |
|-----------|---|---|--|--|--|--|
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable If YES, please describe those key factors that could drive this behaviour in sufficient detail. | | | | | |
| | Impact | Description | | | | |
| | Insert text | Insert text | | | | |
| | (Add additio | nal rows as necessary) | | | | |
| EIA 23 | Do you foresee the implementation of the ICS having an impact on asset concentration risk, either within your own business or across insurance markets in your region? | | | | | |
| | Provide your response by placing an 'x' in the relevant cell: YES NO Not Applicable | | | | | |
| | ii i Lo, piea | se provide a description of the circumstances in which this might occur | | | | |
| | Impact | Description | | | | |



| | Insert text | Insert text |
|-----------|----------------|--|
| | (Add additio | nal rows as necessary) |
| EIA 24 | - | see the implementation of the ICS significantly altering your investment strategy nt decisions in response to stressed market conditions? |
| | YES | ur response by placing an 'x' in the relevant cell: NO Not Applicable se describe the circumstances in which this might occur. |
| | Impact | Description |
| | Insert text | Insert text |
| | (Add additio | nal rows as necessary) |
| EIA 25 | for specific a | see the implementation of the ICS resulting in a significant change in the demand asset classes (eg AAA / BBB rated corporate or government bonds, equities) insurance market? |
| | YES | ur response by placing an 'x' in the relevant cell: NO Not Applicable se describe in sufficient detail the potential impact of each affected asset class. |
| | Asset class | s Description |
| | Insert text | |
| | (Add additio | nal rows as necessary) |
| EIA 26 | | by other areas of the financial markets (eg derivatives or securitisations) that might — directly or indirectly — by the implementation of the ICS? |



| | Provide your response by placing an 'x' in the relevant cell: | | | |
|-----------|---|--|--|--|
| | YES | NO Not Applicable | | |
| | | | | |
| | If YES, please describ | be the specific area of the markets and how it might be impacted. | | |
| | | | | |
| | Impact | Description | | |
| | Insert text | | | |
| | | | | |
| | (Add additional rows a | as necessary) | | |
| EIA 27 | | cerns over the availability of longer-term assets in the market to meet a result of the introduction of the ICS? | | |
| | Provide your respon | se by placing an 'x' in the relevant cell: | | |
| | YES | NO Not Applicable | | |
| | | | | |
| | If YES, please describ where this might beco | be the specific asset types affected and any specific financial conditions me a concern. | | |
| | 3 | | | |
| | Impact | Description | | |
| | Insert text | | | |
| | | | | |
| | (Add additional rows a | as necessary) | | |
| EIA 28 | Do you foresee any increased risk to the broader financial markets (eg from significant reallocations into or out of specific asset classes in response to shocks in financial markets) as a result of the implementation of the ICS? | | | |
| | Provide your respon | se by placing an 'x' in the relevant cell: | | |
| | YES | NO Not Applicable | | |
| | <u> </u> | | | |
| | | | | |



| | If YES, please descri | be those risks in sufficient detail. |
|--|---|---|
| | Asset Class | Description |
| | Insert text | |
| | | |
| | (Add additional rows | as necessary) |
| EIA 29 | Do you foresee any b ICS? | penefits to the insurance market as a result of the implementation of the |
| | Provide your respon | nse by placing an 'x' in the relevant cell: |
| | YES | NO Not Applicable |
| | If YES, please descri | be those benefits in sufficient detail. |
| | Benefit | Description |
| | Insert text | |
| | | |
| | (Add additional rows | as necessary) |
| Implen | nenting the ICS | |
| The pro across includir implem costs o | ocess to implement the regions due to the difference of the timing and use of entation. At this stage of the implementation of usiness might be involved. | ICS will vary significantly between insurers and supervisors and erent local circumstances. The nature of the implementation, if transitional measures will impact the direct and indirect costs of of development of the ICS, it will be difficult to estimate the specific of the ICS. However, we would like to understand what aspects of ed the implementation process and any issues you foresee with |
| EIA 30 | | ean be predicted, do you foresee having to devote significant ent the requirements of the ICS within your business? |
| | Provide your respon | nse by placing an 'x' in the relevant cell: |

Not Applicable

YES

NO



| | If YES, please provide a description of the areas of your business most likely to be affected (eg IT, actuarial, pricing). | | |
|-----------|--|---|--|
| | Business area | Description | |
| | Insert text | Insert text | |
| | (Add addition | nal rows as necessary) | |
| EIA 31 | | t that it can be predicted, do you foresee significant impediments to g the requirements of the ICS within your business? | |
| | Provide you | ur response by placing an 'x' in the relevant cell: NO Not Applicable | |
| | If YES, pleas | se provide a description of issues that might be encountered. | |
| | Impact | Description | |
| | Insert text | Insert text | |
| | (Add addition | nal rows as necessary) | |
| EIA 32 | | osts of implementing the ICS be absorbed by, or shared with, other ion projects running concurrently (eg IFRS 17)? | |
| | Provide you | ur response by placing an 'x' in the relevant cell: NO Not Applicable | |
| | If YES, please provide information on the specific projects and which type of costs could be shared. | | |
| | Impact | Description | |
| | Insert text | Insert text | |



| | (Add additional rows as necessary) | | |
|-----------|---|---|--|
| EIA 33 | Do you foresee any other impacts from the implementation of the ICS, not covered above? | | |
| | Provide your response by placing an 'x' in the relevant cell: | | |
| | YES | NO Not Applicable | |
| | If YES, please provide | ES, please provide information in sufficient detail | |
| | Impact | Description | |
| | Insert text | | |
| | | | |
| | (Add additional rows as necessary) | | |